Atorvastatin medullar thyroid cancer over TT cell line impact of apoptosis and calcitonin over gene expression
Bildiriler > Özet Bildiri
Yazarlar: Emine Kartal Baykan, Çığır BİRAY AVCI, Mehmet ERDOĞAN, Şevki ÇETİNKALP, A Gokhan Ozgen, Cumhur GÜNDÜZ, Lütfiye Füsun SAYGILI
Endocrine Abstracts, , , Uluslararası, Özet Bildiri
Özet
Medullar thyroid cancer (MTC) constitutes 5% of thyroid cancers. 25% of MTC are familial. Mutations activating "germ-line" in RET protooncogene are responsible from genetic inharitance. RET mutation causing tyrosine kinase activation result in oncogenic cell proliferation. Persistent and recurrence disease management is complicated in medullary thyroid cancer because it is unresponsive to chemo, radio and radioactive iodine therapy. Agents targeting thyrosine kinase and RET receptor activity can be used in this case. Tyrosine kinas inhibitors have potential to stabilize metastatic disease, but has no effect on survival, they have many serios side effects. Many studies show that statins, inhibit canser growth by inhibiting HMG Co A reductase through supressing mevolonate pathway. In the present study, through TT cell line we investigated atorvastatin's apoptotic impact in MTC cells and also it is effect on calcitonin gene expression.